BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 26416056)

  • 21. Survival of metastatic germ cell cancer patients assessed by international germ cell consensus classification in Japan.
    Shintaku I; Satoh M; Okajima E; Fujimoto H; Kamoto T; Ogawa O; Kawai K; Akaza H; Tsukamoto T; Naito S; Miki T; Arai Y
    Jpn J Clin Oncol; 2008 Apr; 38(4):281-7. PubMed ID: 18321891
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Analysis of clinical-pathologic variables, staging and prognostic groups, and therapeutic results of 106 germ-cell testicular tumors.
    Bonet AS; Muñoz-Delgado EG; Vico FJ; Ruiz JC; Chapado MS
    Arch Esp Urol; 2011 Dec; 64(10):972-80. PubMed ID: 22228895
    [TBL] [Abstract][Full Text] [Related]  

  • 23. APAF-1 is related to an undifferentiated state in the testicular germ cell tumor pathway.
    Behjati R; Kawai K; Inadome Y; Kano J; Akaza H; Noguchi M
    Cancer Sci; 2011 Jan; 102(1):267-74. PubMed ID: 20977544
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Differential expression of the c-kit proto-oncogene in germ cell tumours.
    Izquierdo MA; Van der Valk P; Van Ark-Otte J; Rubio G; Germa-Lluch JR; Ueda R; Scheper RJ; Takahashi T; Giaccone G
    J Pathol; 1995 Nov; 177(3):253-8. PubMed ID: 8551387
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic analysis of Japanese men with metastatic germ cell tumors showing favorable response to bleomycin, etoposide and cisplatin as first-line chemotherapy.
    Kumano M; Miyake H; Hara I; Muramaki M; Takenaka A; Fujisawa M
    Hinyokika Kiyo; 2007 Dec; 53(12):851-6. PubMed ID: 18203521
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Molecular biomarkers as potential targets for therapeutic strategies in human testicular germ cell tumors: an overview.
    Chieffi P; Chieffi S
    J Cell Physiol; 2013 Aug; 228(8):1641-6. PubMed ID: 23359388
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Human placental alkaline phosphatase (hPLAP) is the most frequently elevated serum marker in testicular cancer].
    Neumann A; Keller T; Jocham D; Doehn C
    Aktuelle Urol; 2011 Sep; 42(5):311-5. PubMed ID: 21809268
    [TBL] [Abstract][Full Text] [Related]  

  • 28. K-RAS and N-RAS mutations in testicular germ cell tumors.
    Hacioglu BM; Kodaz H; Erdogan B; Cinkaya A; Tastekin E; Hacibekiroglu I; Turkmen E; Kostek O; Genc E; Uzunoglu S; Cicin I
    Bosn J Basic Med Sci; 2017 May; 17(2):159-163. PubMed ID: 28426398
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic factors in patients progressing after cisplatin-based chemotherapy for malignant non-seminomatous germ cell tumours.
    Fosså SD; Stenning SP; Gerl A; Horwich A; Clark PI; Wilkinson PM; Jones WG; Williams MV; Oliver RT; Newlands ES; Mead GM; Cullen MH; Kaye SB; Rustin GJ; Cook PA
    Br J Cancer; 1999 Jul; 80(9):1392-9. PubMed ID: 10424741
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Disparities in stage at diagnosis among adults with testicular germ cell tumors in the National Cancer Data Base.
    Lerro CC; Robbins AS; Fedewa SA; Ward EM
    Urol Oncol; 2014 Jan; 32(1):23.e15-21. PubMed ID: 23395701
    [TBL] [Abstract][Full Text] [Related]  

  • 31. p53 and MDM2 expression in primary and metastatic testicular germ cell tumors: Association with clinical outcome.
    Lobo J; Alzamora MA; Guimarães R; Cantante M; Lopes P; Braga I; Maurício J; Jerónimo C; Henrique R
    Andrology; 2020 Sep; 8(5):1233-1242. PubMed ID: 32384200
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Analysis of 7 immunohistochemical markers in male germ cell tumors demonstrates the prognostic significance of p53 and MIB-1.
    Pectasides D; Papaxoinis G; Nikolaou M; Valavanis C; Aravantinos G; Fountzilas G; Tamvakis N; Pectasides E; Lekka I; Arapantoni-Dadioti P; Zizi A; Ghiconti I; Economopoulos T
    Anticancer Res; 2009 Feb; 29(2):737-44. PubMed ID: 19331230
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Estrogen receptor-binding fragment-associated gene 9 expression and its clinical significance in human testicular cancer.
    Fujimura T; Takahashi S; Urano T; Xiaoqiang L; Ogushi T; Muramatsu M; Ouchi Y; Kitamura T; Homma Y; Inoue S
    Int J Urol; 2009 Mar; 16(3):329-32. PubMed ID: 19207611
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Germ cell tumors of the gonads: a selective review emphasizing problems in differential diagnosis, newly appreciated, and controversial issues.
    Ulbright TM
    Mod Pathol; 2005 Feb; 18 Suppl 2():S61-79. PubMed ID: 15761467
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Expression of human chorionic gonadotropin in testicular germ cell tumors.
    Lempiäinen A; Sankila A; Hotakainen K; Haglund C; Blomqvist C; Stenman UH
    Urol Oncol; 2014 Jul; 32(5):727-34. PubMed ID: 24502963
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Absence of c-KIT and members of the epidermal growth factor receptor family in refractory germ cell cancer.
    Kollmannsberger C; Mayer F; Pressler H; Koch S; Kanz L; Oosterhuis JW; Looijenga LH; Bokemeyer C
    Cancer; 2002 Jul; 95(2):301-8. PubMed ID: 12124830
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mutations of c-kit gene in bilateral testicular germ cell tumours in Japan.
    Sakuma Y; Matsukuma S; Yoshihara M; Sakurai S; Nishii M; Kishida T; Kubota Y; Nagashima Y; Inayama Y; Sasaki T; Nakamura Y; Miura T; Kameda Y; Tsuchiya E; Miyagi Y
    Cancer Lett; 2008 Jan; 259(1):119-26. PubMed ID: 18006222
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Predictive tissue markers in testicular germ cell tumors: Immunohistochemical expression of MLH1 and REV-7 proteins.
    Spinos T; Zografos E; Koutsoukos K; Zagouri F; Kosmas C; Driva TS; Goutas D; Gakiopoulou C; Agrogiannis G; Theochari E; Tzavara C; Lazaris AC
    Int Urol Nephrol; 2024 Jun; 56(6):1887-1898. PubMed ID: 38285100
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A risk-adapted study of cisplatin and etoposide, with or without ifosfamide, in patients with metastatic seminoma: results of the GETUG S99 multicenter prospective study.
    Fizazi K; Delva R; Caty A; Chevreau C; Kerbrat P; Rolland F; Priou F; Geoffrois L; Rixe O; Beuzeboc P; Malhaire JP; Culine S; Aubelle MS; Laplanche A
    Eur Urol; 2014 Feb; 65(2):381-6. PubMed ID: 24094847
    [TBL] [Abstract][Full Text] [Related]  

  • 40. COX-2, c-KIT and HER-2/neu expression in uterine carcinosarcomas: prognostic factors or potential markers for targeted therapies?
    Raspollini MR; Susini T; Amunni G; Paglierani M; Taddei A; Marchionni M; Scarselli G; Taddei GL
    Gynecol Oncol; 2005 Jan; 96(1):159-67. PubMed ID: 15589595
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.